Drug recall: These Lots of Levothyroxine sodium Oral Solution recalled

To date, IBSA Pharma Inc. has not received any reports of adverse events that have been determined to be related to this voluntary recall.

513
Drug recall
Drug recall

Last Updated on October 10, 2024 by The Health Master

IBSA Pharma Inc. is voluntarily recalling 27 lots of TIROSINT®-SOL (levothyroxine sodium) Oral Solution to the consumer level.

This voluntary recall has been initiated because these lots may be subpotent. The company’s analyses show a slight decrease below 95.0% of its labeled amount in levothyroxine sodium (T4) for some lots.

Risk Statement: 

Patients being treated for hypothyroidism (underactive thyroid), who receive subpotent TIROSINT®-SOL, may experience signs and symptoms of hypothyroidism (underactive thyroid) which may include, fatigue, increased sensitivity to cold, constipation, dry skin, puffy face, hair loss, slow heart rate, depression, swelling of the thyroid gland and/or unexplained weight gain or difficulty losing weight.

Over- or under-treatment with TIROSINT® SOL may have negative effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, emotional state, gastrointestinal function, and glucose and lipid metabolism.

Any patients including those who might be pregnant, newborn infants, or elderly patients, should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

To date, IBSA Pharma Inc. has not received any reports of adverse events that have been determined to be related to this voluntary recall.

This drug is indicated for:

  • Hypothyroidism – As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
  • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression – As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer.

The product description, NDC numbers, lot numbers, and expiration dates of affected drug lots are shown in the table below:

Product DescriptionNDCLot NumberExpiration Date
TIROSINT-SOL 13 mcg/mL 30 units carton-box71858-0105-522040910/2023
TIROSINT-SOL 13 mcg/mL 30 units carton-box71858-0105-522095603/2024
TIROSINT-SOL 25 mcg/mL 30 units carton-box71858-0110-522085602/2024
TIROSINT-SOL 37.5 mcg/mL 30 units carton-box71858-0112-522055211/2023
TIROSINT-SOL 37.5 mcg/mL 30 units carton-box71858-0112-522105504/2024
TIROSINT-SOL 44 mcg/mL 30 units carton-box71858-0113-522055311/2023
TIROSINT-SOL 44 mcg/mL 30 units carton-box71858-0113-522105604/2024
TIROSINT-SOL 50 mcg/mL 30 units carton-box71858-0115-522040710/2023
TIROSINT-SOL 50 mcg/mL 30 units carton-box71858-0115-522096003/2024
TIROSINT-SOL 62.5 mcg/mL 30 units carton-box71858-0117-522055611/2023
TIROSINT-SOL 62.5 mcg/mL 30 units carton-box71858-0117-522105804/2024
TIROSINT-SOL 75 mcg/mL 30 units carton-box71858-0120-522085302/2024
TIROSINT-SOL 88 mcg/mL 30 units carton-box71858-0125-522041110/2023
TIROSINT-SOL 88 mcg/mL 30 units carton-box71858-0125-522085402/2024
TIROSINT-SOL 100 mcg/mL 30 units carton-box71858-0130-522041310/2023
TIROSINT-SOL 100 mcg/mL 30 units carton-box71858-0130-522096403/2024
TIROSINT-SOL 112 mcg/mL 30 units carton-box71858-0135-522041410/2023
TIROSINT-SOL 112 mcg/mL 30 units carton-box71858-0135-522085202/2024
TIROSINT-SOL 112 mcg/mL 30 units carton-box71858-0135-522097003/2024
TIROSINT-SOL 125 mcg/mL 30 units carton-box71858-0140-522085502/2024
TIROSINT-SOL 137 mcg/mL 30 units carton-box71858-0145-522041510/2023
TIROSINT-SOL 137 mcg/mL 30 units carton-box71858-0145-522105204/2024
TIROSINT-SOL 150 mcg/mL 30 units carton-box71858-0150-522095903/2024
TIROSINT-SOL 175 mcg/mL 30 units carton-box71858-0155-522041610/2023
TIROSINT-SOL 175 mcg/mL 30 units carton-box71858-0155-522105304/2024
TIROSINT-SOL 200 mcg/mL 30 units carton-box71858-0160-522041810/2023
TIROSINT-SOL 200 mcg/mL 30 units carton-box71858-0160-522056011/2023

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (USFDA).

Drug recall: Bharat Biotech voluntarily recalls ChiroRaba vaccine due to this reason

Drug recall: Rifampin Capsules recalled due to this reason

Drug recall: Epinephrine API recalled due to this reason

Drug recall: Daptomycin for Injection recalled due to this reason

Drug recall: Vancomycin Hydrochloride Injection recalled due to this reason

Drug recall: 4 lots of Quinapril Tablets recalled due to this reason

NPPA fixed retail price of 18 formulations: February 2023

FDA Chhattisgarh raided various places and seized huge quantity of fake medicines

Latest IPC Alert – Indian Pharmacopoeia Commission

USFDA approves this anemia drug for patients on dialysis

Pharma gets a boost, Rs 1,250 crore set aside for bulk drug, medical device parks

NSQ Drug: Route cause analysis and CAPA

DCGI allows relabeling & re-stickering of drugs: Rule 104A

Light sensitive drugs / medicines: List

Area required for manufacturing of Drugs, Cosmetics, Homoeopathic & Blood Centre

Latest Notifications regarding Pharmaceuticals

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news